Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 10/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60343 | 1.00 | EPHX1 (0.47) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL3635575 | 1.00 | EPHX1 (0.47) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL8820095 | 0.94 | EPHX1 (0.42) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL8820100 | 0.94 | EPHX1 (0.42) | EPHX1GBA1ACHETNFTLR4 | |
| SCHEMBL5276297 | 0.89 | EPHX1 (0.42) | EPHX1ACHETLR4ADORA1 | |
| SCHEMBL1857528 | 0.87 | EPHX1 (0.47) | EPHX1ACHETLR4ADORA1 | |
| SCHEMBL3635578 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL60345 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL15870614 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 | |
| SCHEMBL60344 | 0.84 | TLR4 (0.50) | EPHX1ACHETLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| US-20210393554-A1 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY | BLUEWILLOW BIOLOGICS, INC. (US) | 2021-12-23 | — | — | US | claimed |
| US-20210147817-A1 | THERMOPHILIC DNA POLYMERASE MUTANTS | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2021-05-20 | — | — | US | claimed |
| US-20200405846-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | BLUEWILLOW BIOLOGICS, INC. | 2020-12-31 | — | — | US | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| US-20200237689-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND OTHER RESPIRATORY INFECTIONS USING NANOEMULSION COMPOSITIONS | BLUEWILLOW BIOLOGICS, INC. (US) | 2020-07-30 | — | — | US | claimed |
| CN-111182880-A | WNT compositions and processes performed from serum-free culture conditions | 安卡萨再生疗法公司 | 2020-05-19 | — | — | CN | claimed |
| US-9341633-B2 | Method for pre-treating sample containing glycated hemoglobin | SEKISUI MEDICAL CO., LTD. (JP) | 2016-05-17 | — | — | US | claimed |
| EP-2729169-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | Nanobio Corporation (US) | 2014-05-14 | — | — | EP | claimed |
| EP-1525475-B1 | SENSOR SURFACE COMPRISING AN IMPROVED SIGNAL-NOISE RATIO | MICRONAS HOLDING GMBH (DE) | 2006-11-22 | — | — | EP | claimed |
| US-20060115906-A1 | Sensor surface comprising an improved signal-noise ratio | MICRONAS HOLDING GMBH (DE) | 2006-06-01 | — | — | US | claimed |
| WO-2006045050-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-04-27 | — | — | WO | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1373550-A1 | METHOD OF PREPARING SUPPORTED LIPID FILM MEMBRANES AND USE THEREOF | Biacore AB (SE) | 2004-01-02 | — | — | EP | claimed |
| US-20020182717-A1 | Method of preparing supported lipid film membranes and use thereof | BIACORE AB (SE) | 2002-12-05 | — | — | US | claimed |
| WO-2002072873-A1 | METHOD OF PREPARING SUPPORTED LIPID FILM MEMBRANES AND USE THEREOF | BIACORE AB (SE) | 2002-09-19 | — | — | WO | claimed |
| US-5491093-A | Quantitative determination of lipid, and of co-existing two compounds | CANON KABUSHIKI KAISHA (JP) | 1996-02-13 | — | — | US | claimed |
| US-5480794-A | POLYHYDROXYALKANOATE POLYMERASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND METABOLIX, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0578726-B1 | VIRUS INACTIVATION METHOD | VEGATEC (FR) | 1995-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405846-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | DBI, DLAT, ABHD5 | EPHX1 2261/4885GBA1 260/4885ACHE 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.